Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

almirall s.a - dimetilfumaratas - psoriazė - imunosupresantai - skilarence skiriamas vidutinio sunkumo ir sunkios plokštelinės psoriazės gydymui suaugusiems, kuriems reikalinga sisteminė terapija.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

biogen netherlands b.v. - dimetilfumaratas - išsėtinė sklerozė - imunosupresantai - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

mylan ireland limited - lenalidomidas - daugybinė mieloma - imunosupresantai - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

mylan ireland limited - dimetilfumaratas - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetilfumaratas - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetilfumaratas - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - dimetilfumaratas - skrandyje neirios kietosios kapsulės - 120 mg - dimethyl fumarate

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - dimetilfumaratas - skrandyje neirios kietosios kapsulės - 240 mg - dimethyl fumarate

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

teva gmbh - dimetilfumaratas - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresantai - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).